{"article_title": "Merck's New R&D Chief Plans to Scale Back", "article_keywords": ["setbacks", "vaunted", "scale", "plans", "spending", "results", "vowing", "stay", "rd", "rivals", "chief", "retrenchingnow", "mercks", "staunchly", "research"], "article_url": "http://www.wsj.com/articles/SB10001424127887324755104579076000194129132", "article_text": "When Kenneth Frazier became chief executive of Merck & Co. in early 2011, he staunchly defended the company's vaunted drug-research laboratories, vowing to stay the course on R&D spending while some rivals were retrenching.\n\nNow two and a-half years and 10 or so research setbacks later, the pressure for better results has mounted.\n\n...", "article_metadata": {"article.template": "snippet", "article.created": "2013-09-19T19:39:00.000Z", "article.section": "Business", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "New Merck R&D chief Roger Perlmutter already has shaken up the drug maker's labs and plans more changes, including reducing the number of research projects in which the company invests.", "creator": "@Loftus", "image": {"alt": "New Merck R&D chief says the drug maker is undergoing 'major surgery'", "identifier": "http://si.wsj.net/img/WSJ_Logo_black_social.gif"}, "title": "Merck's New R&D Chief Plans to Scale Back", "site": "@WSJ", "card": "summary"}, "al": {"ios": {"url": "wsj://launch?articleid=SB10001424127887324755104579076000194129132&headline=New%20Merck%20R%26amp%3BD%20chief%20says%20the%20drug%20maker%20is%20undergoing%20%26apos%3Bmajor%20surgery%26apos%3B&weburl=http://www.wsj.com/articles/SB10001424127887324755104579076000194129132"}}, "page.site.product": "WSJ", "keywords": "Merck,MRK,Amgen,AMGN,Pfizer,PFE,Peter S Kim,Kenneth C Frazier", "news_keywords": "Merck,MRK,Amgen,AMGN,Pfizer,PFE,Peter S Kim,Kenneth C Frazier", "article.headline": "New Merck R&D chief says the drug maker is undergoing 'major surgery'", "description": "New Merck R&D chief Roger Perlmutter already has shaken up the drug maker's labs and plans more changes, including reducing the number of research projects in which the company invests.", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB10001424127887324755104579076000194129132&headline=New%20Merck%20R%26amp%3BD%20chief%20says%20the%20drug%20maker%20is%20undergoing%20%26apos%3Bmajor%20surgery%26apos%3B&weburl=http://www.wsj.com/articles/SB10001424127887324755104579076000194129132", "user.type": "nonsubscriber", "article.page": "Business", "page.content.format": "responsive", "article.summary": "New Merck R&D chief Roger Perlmutter already has shaken up the drug maker's labs and plans more changes, including reducing the number of research projects in which the company invests.", "page.site": "wsj", "testkeys": "C", "article.published": "2013-09-19T19:39:00.000Z", "dj.asn": "i-65e8", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"publisher": "https://www.facebook.com/wsj", "image_count": 1, "word_count": 970, "external_link_count": 1}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "New Merck R&D chief Roger Perlmutter already has shaken up the drug maker's labs and plans more changes, including reducing the number of research projects in which the company invests.", "title": "Merck's New R&D Chief Plans to Scale Back", "url": "http://www.wsj.com/articles/SB10001424127887324755104579076000194129132", "image": {"width": 1200, "identifier": "http://si.wsj.net/img/WSJ_Logo_black_social.gif", "height": 630}, "locale": "en_US", "type": "article"}, "author": "Peter Loftus", "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "Merck\u2019s New R&D Chief Plans to Scale Back", "article.type": "Business", "article.id": "SB10001424127887324755104579076000194129132", "user.exp": "default", "article.updated": "2013-09-19T19:39:00.000Z"}, "_id": "\"57477af46914bd0286fd7f78\"", "article_summary": "Now two and a-half years and 10 or so research setbacks later, the pressure for better results has mounted.\nWhen Kenneth Frazier became chief executive of Merck & Co. in early 2011, he staunchly defended the company's vaunted drug-research laboratories, vowing to stay the course on R&D spending while some rivals were retrenching."}